儿童支气管肺炎抗生素序贯治疗临床探究及成本研究.docVIP

儿童支气管肺炎抗生素序贯治疗临床探究及成本研究[摘要] 目的:评价头孢呋辛或头孢呋辛脂序贯治疗儿童支气管肺炎的可行性、疗效及安全性,并进行治疗成本分析。方法:选择静脉头孢呋辛治疗有效的98例支气管肺炎患儿,随机分为序贯治疗组和对照组。序贯治疗组病情稳定后转为头孢呋辛脂口服治疗;对照组继续静滴头孢呋辛,两组均用药至症状体征基本消失。比较两组疗效差异并进行治疗成本分析。结果:序贯治疗组和对照组痊愈率分别为81.6%、83.6%,有效率分别为93.9%、95.9%,两组治愈率和有效率相比,差异均无统计学意义(P0.05),两组均无明显不良反应发生。序贯治疗组抗生素费用及医疗总费用治疗显著低于对照组。结论:头孢呋辛序贯治疗儿童支气管肺炎不但安全、有效,而且更加经济合理。 [关键词] 序贯治疗;头孢呋辛;儿童;支气管肺炎 [中图分类号] R725.7 [文献标识码]A [文章编号]1674-4721(2010)03(a)-029-02 Analysis of efficacy and economic evaluation of sequential therapy with cefuroxime for children with bronchopneumonia PENG Yueming1,LIANG Mo2*,LIU Bin1 (1.Maternal and Child Health Hospital of Changde, Changde 415000, China; 2.Hunan People′s Hospital, Changsha 410005, China) [Abstract] Objective: To evaluate the effect and cost of sequential therapy with cefuroxime in children with bronchipneimonia. Methods: 98 cases of children with bronchipneimonia whose pathogenetic condition had been partly controlled by 3 days treatment with intravenous drop infusion with cefuroxime divided into the SAT group (by sequential therapy) and control group(by persistent intravenous drop infusion with cefuroxime) randomly. The recovery rates, overall efficacy rates and medical costs of the two groups were evaluated. Results: The recovery rates of SAT group and control group were 81.6% and 83.6% respectively(P0.05), and their overall efficacy rates were 93.9% and 95.9% respectively(P0.05). Except the hospital day, there was no significant difference in the clinical effect between SAT group and control group. And no adverse effect were found in the two groups. But the total expenses and antibiotic cost of the medical treatment of SAT group was oviously lower than those of control group. Conclusion: Sequential therapy with cefuroxime for children with bronchopneumonia is not only safe,valid,but more economic reasonable. [Key words] Sequential therapy; Cefuroxime; Children; Bronchipneimonia 肺炎是威胁我国儿童健康的严重疾病,占住院儿童总人数的24.5%～56.2%,而发展中国家小儿肺炎以细菌病原为主,因此,抗生素疗法